STATIN
Landmark clinical trials such as the Scandinavian Simvastatin Survival Study (also known as 4S), the West of Scotland Coronary Prevention Study, the Long-Term Intervention with Pravastatin in Ischemic Disease Trial, the Heart Protection Study, and the Cholesterol and Recurrent Events Trial have solidified the utility of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, for primary and secondary prevention of cardiovascular disease.
Attendees at a meeting of the American Association for Cancer Research learned that while the results of a study conducted at Rutgers University in New Brunswick, NJ, showed that atorva statin (Lipitor) and celecoxib (Celebrex) individually slowed tumor progression from androgen-dependent to androgen-independent status, the two drugs combined had additive growth-inhibiting activity compared with either drug alone.
Acute coronary syndromes (ACS) include the spectrum of clinical conditions ranging from unstable angina to non-Q-wave myocardial infarction (MI) and Q-wave MI.